Lallemand evaluates efficacy of multi-strain probiotic formulation for kids

08 June 2021 | News

Probiokid is offered as a ready-to-market probiotic formulation in different convenient and leading formats Image credit: Lallemand Image credit: Lallemand

Lallemand Health Solutions’ Probiokid, the world’s best-selling pediatric probiotic formulation, makes the scientific news with its most recent review: “Efficacy of a multi-strain probiotic formulation in pediatric populations: A comprehensive review of clinical studies 1” published on June 1, 2021 in Nutrients.

This comprehensive review summarises the clinical studies in infants and children, including the safety studies, to evaluate the efficacy of Probiokid, a specific probiotic for pediatric indications combining Lactobacillus helveticus Rosell-52, Bifidobacterium infantis Rosell-33,

Bifidobacterium bifidum Rosell-71 and fructooligosaccharides. With a total of 28 clinical studies, Probiokid is one of Lallemand Health Solutions' most documented probiotic formulations which can be marketed under different product categories, for different uses, depending on applicable regulatory provisions. The main evidence comprises:

 Twelve studies show that the probiotic significantly increases the efficacy of standard diarrhea treatment regardless of etiology, reducing the risk of unresolved diarrhea (RR 0.31 [0.23; 0.42] p; 0.0001) by 69 per cent.

 In eight studies, the probiotic enhanced immune defenses, assessed by levels of various immune competence and mucosal immunity markers (six studies), and reduced the incidence of common infections (two studies).

 The probiotic improved iron deficiency anaemia treatment efficacy (three studies), reducing the risk of unresolved anaemia by 49 per cent and significantly reducing treatment side effects by 47 per cent.

 Other studies support further investigation into this probiotic for oral candidiasis, eczema, feeding intolerance in premature babies, or hyperbilirubinemia in newborns. 

Probiokid Regulatory Status:

 Probiokid single strains have been authorised for use in infant food in China.  

 Both combination and single strains have been successfully notified as Generally Recognized as Safe (GRAS) to the United States (US) Food and Drug Administration (FDA) for non-exempt infant formula.

 In Canada, the probiotic combination has been granted the following health claims

Probiokid is offered as a ready-to-market probiotic formulation in different convenient and leading formats such as bulk powder, sachets, orodispersible sticks and drops.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

© Copyright 2021. Nuffoods Spectrum. All Rights Reserved.
Website Design & Developed By : SCI Knowledge Interlinks